FDA Notes Theoretical Cancer Risk For Centocor’s Ustekinumab
This article was originally published in The Pink Sheet Daily
Executive Summary
MAb for psoriasis has favorable odds for a June 17 recommendation by advisory panel, analysts say.
You may also be interested in...
FDA Panel Unanimously Recommends Centocor’s Ustekinumab
But Dermatologic and Ophthalmic Drugs panel says the proposal for long-term safety follow-up is inadequate.
FDA Panel Unanimously Recommends Centocor’s Ustekinumab
But Dermatologic and Ophthalmic Drugs panel says the proposal for long-term safety follow-up is inadequate.
Promacta, Doribax Applications Get Advisory Committee Reviews
Amgen’s Enbrel will also be reviewed for a pediatric psoriasis indication.